Status:
COMPLETED
PROTECT-TIMI 30 Trial
Lead Sponsor:
Millennium Pharmaceuticals, Inc.
Conditions:
Unstable Angina
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
The primary purpose of this study was to compare the efficacy and safety of bivalirudin to eptifibatide (with or without unfractionated heparin or enoxaparin)given to subjects at high risk for heart a...
Detailed Description
Platelet inhibitor drugs
Eligibility Criteria
Inclusion
- Chest paing/discomfort that occurs at rest and lasts at least 10 minutes and have at least one of the following high-risk features:
- diabetes
- elevated cardiac proteins in the blood (indicating acute coronary syndrome)
- Be willing and able to give informed consent
Exclusion
- uncontrolled hypertension
- cardiac episode (heart attack) within the previous 24 hours before randomization into the trial
- prior heart surgery (PCI) within the previous 2 weeks before randomizing in the trial
- any electorcardogram (ECG) finding that make the Holter monitor for ischemia unable to read
Key Trial Info
Start Date :
May 1 2003
Trial Type :
INTERVENTIONAL
End Date :
September 1 2004
Estimated Enrollment :
900 Patients enrolled
Trial Details
Trial ID
NCT00250471
Start Date
May 1 2003
End Date
September 1 2004
Last Update
November 8 2005
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.